ClinicalTrials.gg
CompletedNCT04518995THRIVE-AA1Updated May 3, 2023Results posted

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

A Phase 3 interventional study of CTP-543 matching placebo and CTP-543 in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 72 sites in 5 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
706
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.

Enrollment
2nd of 10
706 · median 336
Started
2020
the only one that year
Phase 3
5 of 10
2 open now
Registered
5th of 10
by date
Lead sponsor
6 of 10
Concert Pharmaceuticals

Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 5 in phase 3, and was the 5th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About deuruxolitinib

Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing deuruxolitinib in Alopecia Areata, or all of them as a file.
02

Study summary

This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.

03

Conditions studied

  • Alopecia Areata

Keywords

  • Alopecia
  • Hair loss
  • Hair disease
  • CTP-543
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
  • At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
  • Willing to comply with the study visits and requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response.
  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline.
  • Treatment with systemic medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study.
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
  • medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
706 participants (actual)

Study arms

  • Experimental
    Placebo

    Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.

    Drug: CTP-543 matching placebo

  • Experimental
    CTP-543 8 mg BID

    Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.

    Drug: CTP-543

  • Placebo comparator
    CTP-543 12 mg BID

    Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.

    Drug: CTP-543

Interventions

  • DrugCTP-543 matching placebo

    Administered as tablets.

  • Administered as tablets.

  • Administered as tablets.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24

    SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Responders were defined as participants with responses of "satisfied" or "very satisfied".

    Time frame: Weeks 12, 16, 20, and 24

  2. Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

    Time frame: Weeks 4, 8, 12, 16, and 20

  3. Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  4. Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24

    The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

    Time frame: Weeks 12, 16, 20, and 24

  5. Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24

    The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

    Time frame: Weeks 12, 16, 20, and 24

  6. Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

    The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  7. Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

    The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  8. Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Percentage of participants achieving at least a 75% and 90% relative reduction in SALT score from baseline at Weeks 12 and 24 are reported.

    Time frame: Baseline, Weeks 12, and 24

  9. Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24

    BETA is a clinician-rated scale that assesses the total eyebrow hair present. The BETA score is calculated based on hair density and surface area of each individual eyebrow of the participant, ranging from 0 to 3, where 0 = no eyebrow, 1 = minimal eyebrow, 2 = moderate eyebrow, 3 = normal eyebrow. The BETA score is the sum of the right and left eyebrow scores, ranging from 0 to 6. Higher scores indicate less hair loss of eyebrows. A positive change from baseline indicates less hair loss of eyebrows.

    Time frame: Baseline, Weeks 12, and 24

  10. Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24

    BELA is a clinician-rated scale that assesses the total eyelash hair present. The BELA is calculated based on distribution and grade values, ranging from 0 (no eyelashes) to 3 (full eyelashes). The BELA score is the sum of the individual scores for the left and right eyes, ranging from 0 to 6. Higher scores indicate less hair loss of eyelashes. A positive change from baseline indicates less hair loss of eyelashes.

    Time frame: Baseline, Weeks 12, and 24

  11. Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24

    SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  12. Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24

    SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied.

    Time frame: Weeks 12, 16, 20, and 24

  13. Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24

    The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicate the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  14. Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24

    HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

    Time frame: Baseline and Week 24

  15. Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

    Time frame: Week 24

07

Results

Posted May 3, 2023

Participant flow

Participants were enrolled at study centers in Canada, France, Poland, Spain and the United States from 23 November 2020 to 19 April 2022.

Participant flow — Overall Study
MilestonePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Started140351215
Efficacy population140351215
Safety population140350215
Completed129318199
Not completed113316
Withdrew: Treatment emergent or worsening adverse event284
Withdrew: Lack of efficacy210
Withdrew: Non-compliance with study drug032
Withdrew: Pregnancy001
Withdrew: Protocol violation201
Withdrew: Reason not specified4112
Withdrew: Lost to follow-up1106

Outcome measures

PrimaryPercentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 24
percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score of ≤20 at Week 240.829.641.5
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.28 · 95% CI 0.23 to 0.33
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.39 · 95% CI 0.32 to 0.46
SecondaryPercentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Responders were defined as participants with responses of "satisfied" or "very satisfied".

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · percentage of responders
Percentage of Responders on the Hair Satisfaction Patient Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24
percentage of respondersPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 1211.935.346.4
Week 168.338.251.5
Week 206.137.454.0
Week 244.742.153.0
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.25 · 95% CI 0.17 to 0.32
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.35 · 95% CI 0.26 to 0.43
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.31 · 95% CI 0.24 to 0.38
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.43 · 95% CI 0.35 to 0.51
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.32 · 95% CI 0.26 to 0.39
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.47 · 95% CI 0.39 to 0.55
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.38 · 95% CI 0.31 to 0.44
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.47 · 95% CI 0.39 to 0.55
SecondaryPercentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Time frame:
Weeks 4, 8, 12, 16, and 20
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20
percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 400.90
Week 803.36.1
Week 120.710.418.2
Week 162.316.529.6
Week 200.824.137.0
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = 0.0816 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.01 · 95% CI -0.00 to 0.02
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = 0.0005 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.03 · 95% CI 0.01 to 0.05
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = 0.0002 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.06 · 95% CI 0.03 to 0.09
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.10 · 95% CI 0.06 to 0.14
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.17 · 95% CI 0.12 to 0.22
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.14 · 95% CI 0.10 to 0.19
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.27 · 95% CI 0.20 to 0.33
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.23 · 95% CI 0.19 to 0.28
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.35 · 95% CI 0.28 to 0.41
SecondaryRelative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · percent change
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
percent changePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Relative Change From Baseline at Week 4-0.2 ± 5.59-2.6 ± 12.79-4.0 ± 12.03
Relative Change From Baseline at Week 8-2.3 ± 11.41-10.9 ± 21.0017.5 ± 27.16
Relative Change From Baseline at Week 12-0.6 ± 16.63-22.2 ± 29.45-31.1 ± 35.53
Relative Change From Baseline at Week 16-1.8 ± 21.06-30.3 ± 34.20-41.2 ± 38.95
Relative Change From Baseline at Week 20-1.3 ± 22.14-36.0 ± 37.82-46.8 ± 41.32
Relative Change From Baseline at Week 24-1.5 ± 23.30-41.2 ± 39.37-50.4 ± 41.52
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = 0.0564 (P-value was calculated by mixed model repeated measures (MMRM) analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Least square (ls) mean difference: -2.2 · 95% CI -4.4 to 0.1
  • Placebo vs CTP-543 12 mg BID · MMRM · p = 0.0054 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -3.4 · 95% CI -5.9 to -1.0
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -8.5 · 95% CI -12.7 to -4.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -14.9 · 95% CI -19.5 to -10.3
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -21.7 · 95% CI -27.5 to -16.0
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -30.0 · 95% CI -36.3 to -23.8
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -28.4 · 95% CI -35.1 to -21.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -38.5 · 95% CI -45.7 to -31.3
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -34.9 · 95% CI -42.1 to -27.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -44.6 · 95% CI -52.3 to -36.8
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -39.3 · 95% CI -46.7 to -31.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -47.0 · 95% CI -55.1 to -39.0
SecondaryPercentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24

The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · percentage of responders
Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24
percentage of respondersPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 123.736.343.5
Week 167.744.254.7
Week 208.449.157.1
Week 249.453.859.8
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by cochran mantel haenszel (CMH) test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
SecondaryPercentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24

The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · percentage of responders
Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24
percentage of respondersPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 126.738.949.8
Week 169.049.158.3
Week 2010.050.660.0
Week 2410.256.665.5
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
SecondaryChange in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline6.5 ± 0.746.4 ± 0.866.4 ± 0.76
Change From Baseline at Week 12-0.1 ± 0.74-1.0 ± 1.38-1.4 ± 1.53
Change From Baseline at Week 16-0.2 ± 0.99-1.3 ± 1.55-1.9 ± 1.77
Change From Baseline at Week 20-0.1 ± 0.83-1.6 ± 1.77-2.2 ± 1.92
Change From Baseline at Week 24-0.2 ± 0.90-1.9 ± 1.89-2.4 ± 2.03
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.2 to -0.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.5 to -0.9
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.4 to -0.9
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.6 · 95% CI -1.9 to -1.3
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.5 · 95% CI -1.8 to -1.2
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.9 · 95% CI -2.3 to -1.6
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.7 · 95% CI -2.0 to -1.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -2.1 · 95% CI -2.5 to -1.7
SecondaryChange in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline6.5 ± 0.766.5 ± 0.806.4 ± 0.86
Change From Baseline at Week 12-0.4 ± 1.08-1.1 ± 1.64-1.4 ± 1.79
Change From Baseline at Week 16-0.2 ± 0.78-1.5 ± 1.83-2.0 ± 1.95
Change From Baseline at Week 20-0.3 ± 1.01-1.8 ± 2.01-2.2 ± 2.07
Change From Baseline at Week 24-0.1 ± 0.74-1.9 ± 2.05-2.4 ± 2.14
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.6 · 95% CI -0.9 to -0.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.3 to -0.6
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.6 to -0.9
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.7 · 95% CI -2.1 to -1.4
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.4 · 95% CI -1.7 to -1.0
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.9 · 95% CI -2.3 to -1.5
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.7 · 95% CI -2.0 to -1.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -2.2 · 95% CI -2.6 to -1.8
SecondaryPercentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Percentage of participants achieving at least a 75% and 90% relative reduction in SALT score from baseline at Weeks 12 and 24 are reported.

Time frame:
Baseline, Weeks 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24
percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
75% Relative Reduction: Week 1208.817.7
75% Relative Reduction: Week 24028.640.0
90% Relative Reduction: Week 1203.410.0
90% Relative Reduction: Week 24019.232.0
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.09 · 95% CI 0.06 to 0.12
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.17 · 95% CI 0.12 to 0.22
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.28 · 95% CI 0.23 to 0.33
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.38 · 95% CI 0.32 to 0.45
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = 0.0006 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.04 · 95% CI 0.02 to 0.06
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.10 · 95% CI 0.06 to 0.14
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.19 · 95% CI 0.15 to 0.23
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.30 · 95% CI 0.24 to 0.37
SecondaryChange in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24

BETA is a clinician-rated scale that assesses the total eyebrow hair present. The BETA score is calculated based on hair density and surface area of each individual eyebrow of the participant, ranging from 0 to 3, where 0 = no eyebrow, 1 = minimal eyebrow, 2 = moderate eyebrow, 3 = normal eyebrow. The BETA score is the sum of the right and left eyebrow scores, ranging from 0 to 6. Higher scores indicate less hair loss of eyebrows. A positive change from baseline indicates less hair loss of eyebrows.

Time frame:
Baseline, Weeks 12, and 24
Reported as:
Mean · score on a scale
Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24
score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline1.7 ± 2.051.2 ± 1.771.4 ± 1.91
Change From Baseline at Week 12-0.2 ± 1.380.8 ± 1.701.1 ± 2.05
Change From Baseline at Week 24-0.2 ± 1.681.6 ± 1.961.8 ± 2.17
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = 0.0010 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 0.7 · 95% CI 0.3 to 1.2
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.1 · 95% CI 0.6 to 1.6
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.7 · 95% CI 1.2 to 2.2
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.9 · 95% CI 1.4 to 2.4
SecondaryChange in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24

BELA is a clinician-rated scale that assesses the total eyelash hair present. The BELA is calculated based on distribution and grade values, ranging from 0 (no eyelashes) to 3 (full eyelashes). The BELA score is the sum of the individual scores for the left and right eyes, ranging from 0 to 6. Higher scores indicate less hair loss of eyelashes. A positive change from baseline indicates less hair loss of eyelashes.

Time frame:
Baseline, Weeks 12, and 24
Reported as:
Mean · score on a scale
Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24
score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline1.5 ± 2.121.4 ± 2.101.7 ± 2.12
Change From Baseline at Week 12-0.1 ± 1.180.9 ± 1.501.3 ± 2.08
Change From Baseline at Week 240.3 ± 1.301.7 ± 1.992.0 ± 2.28
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 0.9 · 95% CI 0.5 to 1.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.4 · 95% CI 1.0 to 1.8
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.5 · 95% CI 1.0 to 2.0
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.9 · 95% CI 1.4 to 2.4
SecondaryChange in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24
score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline4.5 ± 0.864.5 ± 0.894.5 ± 0.85
Change From Baseline at Week 12-0.6 ± 1.15-1.3 ± 1.42-1.7 ± 1.36
Change From Baseline at Week 16-0.4 ± 1.18-1.4 ± 1.44-1.8 ± 1.43
Change From Baseline at Week 20-0.4 ± 1.14-1.4 ± 1.52-1.8 ± 1.52
Change From Baseline at Week 24-0.3 ± 1.09-1.5 ± 1.54-1.9 ± 1.64
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -0.7 · 95% CI -1.0 to -0.5
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.1 · 95% CI -1.3 to -0.8
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.0 · 95% CI -1.2 to -0.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.4 · 95% CI -1.6 to -1.1
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.1 · 95% CI -1.3 to -0.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.5 · 95% CI -1.7 to -1.2
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.2 · 95% CI -1.5 to -1.0
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.6 · 95% CI -1.8 to -1.3
SecondaryPercentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied.

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24
percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 1220.744.753.1
Week 1614.348.153.9
Week 2013.747.557.5
Week 2412.549.158.0
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.25 · 95% CI 0.17 to 0.34
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.32 · 95% CI 0.23 to 0.42
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.35 · 95% CI 0.27 to 0.42
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.39 · 95% CI 0.30 to 0.48
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.34 · 95% CI 0.26 to 0.42
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.42 · 95% CI 0.34 to 0.51
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.37 · 95% CI 0.29 to 0.44
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.44 · 95% CI 0.35 to 0.53
SecondaryChange in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24

The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicate the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · score on a scale
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Satisfied Thickness Hair Coverage: Baseline4.5 ± 0.794.6 ± 0.794.5 ± 0.76
Satisfied Thickness Hair Coverage: Change From Baseline at Week 12-0.4 ± 0.98-1.1 ± 1.23-1.3 ± 1.17
Satisfied Thickness Hair Coverage: Change From Baseline at Week 16-0.3 ± 1.03-1.2 ± 1.28-1.5 ± 1.33
Satisfied Thickness Hair Coverage: Change From Baseline at Week 20-0.3 ± 0.98-1.3 ± 1.35-1.6 ± 1.36
Satisfied Thickness Hair Coverage: Change From Baseline at Week 24-0.2 ± 1.00-1.4 ± 1.43-1.7 ± 1.45
Satisfied Evenness Hair Coverage: Baseline4.6 ± 0.674.6 ± 0.764.6 ± 0.68
Satisfied Evenness Hair Coverage: Change From Baseline at Week 12-0.4 ± 0.83-1.0 ± 1.19-1.3 ± 1.16
Satisfied Evenness Hair Coverage: Change From Baseline at Week 16-0.3 ± 0.84-1.1 ± 1.31-1.4 ± 1.34
Satisfied Evenness Hair Coverage: Change From Baseline at Week 20-0.3 ± 0.90-1.2 ± 1.36-1.5 ± 1.40
Satisfied Evenness Hair Coverage: Change From Baseline at Week 24-0.2 ± 0.84-1.2 ± 1.41-1.6 ± 1.52
How Satisfied With Your Eyebrows: Baseline3.8 ± 1.394.0 ± 1.283.9 ± 1.35
How Satisfied With Your Eyebrows: Change From Baseline at Week 12-0.2 ± 0.88-1.0 ± 1.20-1.1 ± 1.34
How Satisfied With Your Eyebrows: Change From Baseline at Week 16-0.1 ± 0.90-1.1 ± 1.24-1.3 ± 1.27
How Satisfied With Your Eyebrows: Change From Baseline at Week 20-0.2 ± 0.88-1.2 ± 1.25-1.4 ± 1.32
How Satisfied With Your Eyebrows: Change From Baseline at Week 24-0.2 ± 0.87-1.2 ± 1.26-1.4 ± 1.36
How Satisfied With Your Eyelashes: Baseline3.7 ± 1.443.9 ± 1.373.7 ± 1.44
How Satisfied With Your Eyelashes: Change From Baseline at Week 12-0.3 ± 0.79-0.9 ± 1.21-0.9 ± 1.24
How Satisfied With Your Eyelashes: Change From Baseline at Week 16-0.2 ± 0.97-1.0 ± 1.24-1.2 ± 1.30
How Satisfied With Your Eyelashes: Change From Baseline at Week 20-0.3 ± 0.99-1.1 ± 1.30-1.1 ± 1.33
How Satisfied With Your Eyelashes: Change From Baseline at Week 24-0.2 ± 0.95-1.1 ± 1.37-1.2 ± 1.37
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.7 · 95% CI -0.9 to -0.5
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score) · Ls mean difference: -0.9 · 95% CI -1.2 to -0.7
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.6
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score) · Ls mean difference: -1.2 · 95% CI -1.4 to -1.0
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.2 to -0.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.3 · 95% CI -1.6 to -1.1
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.1 · 95% CI -1.3 to -0.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.4 · 95% CI -1.7 to -1.2
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.6 · 95% CI -0.8 to -0.4
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.7
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.7 · 95% CI -0.9 to -0.5
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.1 · 95% CI -1.3 to -0.8
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.5 to -1.0
  • Placebo vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.2 to -0.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM mixed model repeated measures analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.3 · 95% CI -1.5 to -1.0
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.7 · 95% CI -0.9 to -0.5
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.8 · 95% CI -1.1 to -0.6
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.1 · 95% CI -1.4 to -0.9
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.1 · 95% CI -1.3 to -0.9
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.2 to -0.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.4 to -0.9
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.5 · 95% CI -0.7 to -0.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.6 · 95% CI -0.8 to -0.4
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.7 · 95% CI -0.9 to -0.5
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.7
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.7 · 95% CI -0.9 to -0.5
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.8 · 95% CI -1.0 to -0.5
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.6
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.2 to -0.7
SecondaryChange in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24

HADS is a questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

Time frame:
Baseline and Week 24
Reported as:
Mean · score on a scale
Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24
score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Anxiety: Baseline5.5 ± 3.926.2 ± 4.066.0 ± 3.92
Anxiety: Change From Baseline at Week 24-0.4 ± 2.98-1.0 ± 3.26-1.1 ± 3.24
Depression: Baseline3.3 ± 3.063.7 ± 3.313.6 ± 3.39
Depression: Change From Baseline at Week 24-0.7 ± 2.67-0.9 ± 2.93-1.1 ± 2.88
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · ANCOVA · p = 0.2489 (P-value was calculated by analysis of covariance (ANCOVA) analysis with effects for treatment, visit, baseline SALT score, and baseline HADS value.) · Ls mean difference: 0.3 · 95% CI -0.2 to 0.9
  • Placebo vs CTP-543 12 mg BID · ANCOVA · p = 0.1235 (P-value was calculated by ANCOVA analysis with effects for treatment, visit, baseline SALT score, and baseline HADS value.) · Ls mean difference: 0.5 · 95% CI -0.1 to 1.1
  • Placebo vs CTP-543 8 mg BID · ANCOVA · p = 0.9765 (P-value was calculated by ANCOVA analysis with effects for treatment, visit, baseline SALT score, and baseline HADS value.) · Ls mean difference: 0.0 · 95% CI -0.5 to 0.5
  • Placebo vs CTP-543 12 mg BID · ANCOVA · p = 0.3559 (P-value was calculated by ANCOVA analysis with effects for treatment, visit, baseline SALT score, and baseline HADS value.) · Ls mean difference: 0.3 · 95% CI -0.3 to 0.8
SecondaryPercentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24
percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24020.834.5
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.21 · 95% CI 0.16 to 0.25
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.33 · 95% CI 0.27 to 0.39

Adverse events

Collected over All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/140 (0%)4/140 (2.9%)31/140 (22.1%)
CTP-543 8 mg BID0/351 (0%)4/350 (1.1%)117/350 (33.4%)
CTP-543 12 mg BID0/215 (0%)1/215 (0.5%)75/215 (34.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
AppendicitisInfections and infestations1/1401/3501/215
EpilepsyNervous system disorders1/1400/3500/215
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/1400/3500/215
Adjustment disorderPsychiatric disorders1/1400/3500/215
IleusGastrointestinal disorders0/1400/3501/215
COVID-19Infections and infestations0/1401/3500/215
MeningitisInfections and infestations0/1401/3500/215
Chest painGeneral disorders0/1401/3500/215
PyrexiaGeneral disorders0/1401/3500/215
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1401/3500/215
Most frequent other events
Most frequent other events
EventPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
AcneSkin and subcutaneous tissue disorders7/14031/35026/215
HeadacheNervous system disorders8/14041/35024/215
COVID-19Infections and infestations8/14019/35015/215
Upper respiratory tract infectionInfections and infestations9/1409/3508/215
Blood creatine phosphokinase (increased)Investigations2/14021/35011/215
NasopharyngitisInfections and infestations5/14018/3508/215

Baseline characteristics

All randomized participants included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(years)PlaceboCTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Mean38.7 ± 13.8138.9 ± 13.3238.2 ± 12.8038.6 ± 13.25
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Female89217131437
Male5113484269
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Hispanic or Latino11301354
Not Hispanic or Latino119292188599
Unknown or Not Reported10291453
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Race — American Indian or Alaska Native0213
Race — Asian10222153
Race — Black or African American16402783
Race — Native Hawaiian or other Pacific Islander1315
Race — White98241145484
Race — Other517628
Race — Not reported10261450
08

Study locations

72 sites
  • Total Skin and Beauty Dermatology Center
    Birmingham, Alabama 35205, United States
  • Kern Research, Inc.
    Bakersfield, California 93301, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • UC Irvine Dermatology Clinical Research Center
    Irvine, California 92697, United States
  • Quest Dermatology Research
    Northridge, California 91324, United States
  • Kaiser Permanente
    Oakland, California 94611, United States
  • Kaiser Permanente South Sacramento
    Sacramento, California 95823, United States
  • Kaiser Permanente
    San Francisco, California 94118, United States
  • Colorado Center for Dermatology and Skin Surgery
    Centennial, Colorado 80111, United States
  • Colorado Medical Research Center
    Denver, Colorado 80210, United States
  • Yale University, Church Street Research Unit
    New Haven, Connecticut 06519, United States
  • Lenus Research & Medical Group, LLC
    Sweetwater, Florida 33172, United States
  • Clinical Research Trials of Florida, Inc.
    Tampa, Florida 33607, United States
  • Forward Clinical Trials Inc.
    Tampa, Florida 33624, United States
  • Denova Research
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital, Department of Dermatology
    Chicago, Illinois 60611, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • DS Research
    New Albany, Indiana 47150, United States
  • The Indiana Clinical Trials Center, PC
    Plainfield, Indiana 46168, United States
  • DS Research
    Louisville, Kentucky 40241, United States
  • Qualmedica Research LLC
    Owensboro, Kentucky 42301, United States
  • Massachusetts General Hospital - Clinic
    Boston, Massachusetts 02114, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Clarkston Skin Research
    Clarkston, Michigan 48346, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • University of Minnesota Department of Dermatology
    Minneapolis, Minnesota 55455, United States
  • Skin Laser and Surgery Specialists of NJ
    Hackensack, New Jersey 07601, United States
  • Sadick Research Group
    New York, New York 10075, United States
  • Darst Dermatology
    Charlotte, North Carolina 28277, United States
  • Dermatology Specialists of Charlotte
    Charlotte, North Carolina 28277, United States
  • Wake Forest University Health Sciences, Department of Dermatology
    Winston-Salem, North Carolina 27157, United States
  • Bexley Dermatology Research
    Bexley, Ohio 43209, United States
  • Vital Prospects Clinical Research Institute, P.C.
    Tulsa, Oklahoma 74136, United States
  • Northwest Dermatology Institute
    Portland, Oregon 97210, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Dermatology Associates Of Plymouth Meeting
    Plymouth Meeting, Pennsylvania 19462, United States
  • PEAK Research
    Upper Saint Clair, Pennsylvania 15241, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Clinical Research Center of the Carolinas
    Charleston, South Carolina 29407, United States
  • Palmetto Clinical Trial Services
    Fountain Inn, South Carolina 29644, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401, United States
  • Dermatology Treatment and Research Center
    Dallas, Texas 75230, United States
  • Austin Institute for Clinical Research, Inc.
    Houston, Texas 77056, United States
  • Austin Institute for Clinical Research, Inc.
    Pflugerville, Texas 78660, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • West End Dermatology Associates
    Richmond, Virginia 23233, United States
  • Clinical Investigation Specialists, Inc.
    Kenosha, Wisconsin 53144, United States
  • Dermatology Research Institute
    Calgary, Alberta T1Y 0B4, Canada
  • Kirk Barber Research
    Calgary, Alberta T2G 1B1, Canada
  • Enverus Medical Research
    Surrey, British Columbia V3V 0C6, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • SimcoDerm Medical and Surgical Dermatology Center
    Barrie, Ontario L4M 7G1, Canada
  • Guelph Dermatology Research
    Guelph, Ontario N1L 0B7, Canada
  • Dr Wei Jing Loo Medicine Professional Corporation
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X3, Canada
  • Dr. S. K. Siddha Medicine Professional Corporation
    Newmarket, Ontario L3Y 5G8, Canada
  • The Centre for Clinical Trials
    Oakville, Ontario L6J 7W5, Canada
  • JRB Research Inc.
    Ottawa, Ontario K1H 7X3, Canada
  • Research Toronto
    Toronto, Ontario M4W 2N4, Canada
  • K. Papp Clinical Research Inc.
    Waterloo, Ontario N2J 1C4, Canada
  • Innovaderm Research Inc. - Clinic
    Montreal, Quebec H2X 2V1, Canada
  • Hôpital Saint-André - Chu de Bordeaux
    Bordeaux, Nouvelle-aquitaine 33075, France
  • Hôpital Saint-Louis - Gh de La Rochelle
    La Rochelle, Nouvelle-aquitaine 17000, France
  • Hôpital Hotel Dieu - Chu de Nantes
    Nantes, PAYS DE LA Loire 44093, France
  • Hôpital La Timone-Dermatologie
    Marseille, 13385, France
  • Hôpital Saint Louis, Centre de Santé Sabouraud
    Paris, 75010, France
  • Vita Longa Sp.Zo.O
    Katowice, 40-748, Poland
  • SGD S.C.
    Krakow, 31-147, Poland
  • My Clinic
    Warsaw, 00-144, Poland
  • Royalderm Agnieszka Nawrocka
    Warsaw, 02-962, Poland
  • Hospital Clínico Y Provincial de Barcelona
    Barcelona, 8036, Spain
  • H. U. Ramón y Cajal
    Madrid, 28034, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Apr 2022, 16 months.

Results were first posted in May 2023, 1 year after primary completion.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2020
First posted
Aug 19, 2020
StartActual
Nov 23, 2020
Primary completionActual
Apr 19, 2022
CompletionActual
Apr 19, 2022
Results first posted
May 3, 2023
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04518995
Responsible party
Sponsor
First posted
Aug 19, 2020
Start date
Nov 23, 2020
Primary completion
Apr 19, 2022
Completion
Apr 19, 2022
Results posted
May 3, 2023
Last update
May 3, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion